Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment
Coronavirus disease 2019 (COVID-19) is a pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most infected people have mild or moderate symptoms and recover without the need for extensive treatment. However, for seriously ill patients, no specific treatments are curr...
Gespeichert in:
| Veröffentlicht in: | Frontiers in immunology 2020-09, Vol.11, p.570063-570063, Article 570063 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 570063 |
|---|---|
| container_issue | |
| container_start_page | 570063 |
| container_title | Frontiers in immunology |
| container_volume | 11 |
| creator | Ouyang, Jing Isnard, Stephane Lin, John Fombuena, Brandon Peng, Xiaorong Routy, Jean-Pierre Chen, Yaokai |
| description | Coronavirus disease 2019 (COVID-19) is a pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most infected people have mild or moderate symptoms and recover without the need for extensive treatment. However, for seriously ill patients, no specific treatments are currently available. Convalescent plasma therapy (CPT), a passive immunotherapy, involves infusing plasma from recovered people into actively infected people, and is thought to be a specific intervention to improve outcome in patients with severe COVID-19. The presumed mechanism involves neutralizing antibodies and antibody dependent cytotoxicity/phagocytosis. Previous CPT trials showed an effect in SARS and pilot studies suggest CPT is an effective and safe strategy for seriously ill COVID-19 patients. CPT is currently being tested in large randomized clinical trials. Herein, we critically review the mechanism, applications and the challenges for CPT in the treatment of severe COVID-19, paving the way toward vaccine and immunotherapy development. |
| doi_str_mv | 10.3389/fimmu.2020.570063 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7539593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_2fb2c364342c475b8b41c8e592c900bc</doaj_id><sourcerecordid>2452098291</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-2ea332afcbe90ed532def4ccaf96e2d0c23250a6551eb1bba6fc9c334da805bf3</originalsourceid><addsrcrecordid>eNqNkd9rFDEQxxdRbDn7B_iWR0HuTCbJ3sYHQddfhYIiJz6GSXbSpuxuarJ70v_evV4p9s28JEzm-xmYT1W9FHwjZWPehDgM8wY48I3ecl7LJ9WpqGu1lgDq6T_vk-qslGu-HGWklPp5dSIl34IQ4rT61aZxjz0VT-PEvvdYBnzLdlfEflCPt-wDTmlkcWTToYSeWEiZtSmnEfcxz4V9jIWwEAMuDNtlwmlYUC-qZwH7Qmf396r6-fnTrv26vvj25bx9f7H2SsG0BkIpAYN3ZDh1WkJHQXmPwdQEHfcgQXOstRbkhHNYB2-8lKrDhmsX5Ko6P3K7hNf2JscB861NGO1dIeVLi3mKvicLwYGXtZIKvNpq1zglfEPagDecO7-w3h1ZN7MbqDtsJGP_CPr4Z4xX9jLt7VZLo5fdrqpX94Ccfs9UJjvEZbF9jyOluVhQGrhpwIilVRxbfU6lZAoPYwS3B7_2zq89-LVHv0umOWb-kEuh-Eijp4fc4ldvdc3BHFSLNk44xTS2aR6nJfr6_6PyL6PduSg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452098291</pqid></control><display><type>article</type><title>Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment</title><source>PubMed Central Free</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Ouyang, Jing ; Isnard, Stephane ; Lin, John ; Fombuena, Brandon ; Peng, Xiaorong ; Routy, Jean-Pierre ; Chen, Yaokai</creator><creatorcontrib>Ouyang, Jing ; Isnard, Stephane ; Lin, John ; Fombuena, Brandon ; Peng, Xiaorong ; Routy, Jean-Pierre ; Chen, Yaokai</creatorcontrib><description>Coronavirus disease 2019 (COVID-19) is a pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most infected people have mild or moderate symptoms and recover without the need for extensive treatment. However, for seriously ill patients, no specific treatments are currently available. Convalescent plasma therapy (CPT), a passive immunotherapy, involves infusing plasma from recovered people into actively infected people, and is thought to be a specific intervention to improve outcome in patients with severe COVID-19. The presumed mechanism involves neutralizing antibodies and antibody dependent cytotoxicity/phagocytosis. Previous CPT trials showed an effect in SARS and pilot studies suggest CPT is an effective and safe strategy for seriously ill COVID-19 patients. CPT is currently being tested in large randomized clinical trials. Herein, we critically review the mechanism, applications and the challenges for CPT in the treatment of severe COVID-19, paving the way toward vaccine and immunotherapy development.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2020.570063</identifier><identifier>PMID: 33072111</identifier><language>eng</language><publisher>LAUSANNE: Frontiers Media Sa</publisher><subject>antibody ; convalescent plasma therapy ; coronavirus disease 2019 ; Immunology ; immunotherapy ; Life Sciences & Biomedicine ; Science & Technology ; severe acute respiratory syndrome coronavirus-2</subject><ispartof>Frontiers in immunology, 2020-09, Vol.11, p.570063-570063, Article 570063</ispartof><rights>Copyright © 2020 Ouyang, Isnard, Lin, Fombuena, Peng, Routy and Chen. 2020 Ouyang, Isnard, Lin, Fombuena, Peng, Routy and Chen</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>12</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000575602900001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c442t-2ea332afcbe90ed532def4ccaf96e2d0c23250a6551eb1bba6fc9c334da805bf3</citedby><cites>FETCH-LOGICAL-c442t-2ea332afcbe90ed532def4ccaf96e2d0c23250a6551eb1bba6fc9c334da805bf3</cites><orcidid>0000-0002-2596-969X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539593/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539593/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,27928,27929,28252,53795,53797</link.rule.ids></links><search><creatorcontrib>Ouyang, Jing</creatorcontrib><creatorcontrib>Isnard, Stephane</creatorcontrib><creatorcontrib>Lin, John</creatorcontrib><creatorcontrib>Fombuena, Brandon</creatorcontrib><creatorcontrib>Peng, Xiaorong</creatorcontrib><creatorcontrib>Routy, Jean-Pierre</creatorcontrib><creatorcontrib>Chen, Yaokai</creatorcontrib><title>Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment</title><title>Frontiers in immunology</title><addtitle>FRONT IMMUNOL</addtitle><description>Coronavirus disease 2019 (COVID-19) is a pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most infected people have mild or moderate symptoms and recover without the need for extensive treatment. However, for seriously ill patients, no specific treatments are currently available. Convalescent plasma therapy (CPT), a passive immunotherapy, involves infusing plasma from recovered people into actively infected people, and is thought to be a specific intervention to improve outcome in patients with severe COVID-19. The presumed mechanism involves neutralizing antibodies and antibody dependent cytotoxicity/phagocytosis. Previous CPT trials showed an effect in SARS and pilot studies suggest CPT is an effective and safe strategy for seriously ill COVID-19 patients. CPT is currently being tested in large randomized clinical trials. Herein, we critically review the mechanism, applications and the challenges for CPT in the treatment of severe COVID-19, paving the way toward vaccine and immunotherapy development.</description><subject>antibody</subject><subject>convalescent plasma therapy</subject><subject>coronavirus disease 2019</subject><subject>Immunology</subject><subject>immunotherapy</subject><subject>Life Sciences & Biomedicine</subject><subject>Science & Technology</subject><subject>severe acute respiratory syndrome coronavirus-2</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>DOA</sourceid><recordid>eNqNkd9rFDEQxxdRbDn7B_iWR0HuTCbJ3sYHQddfhYIiJz6GSXbSpuxuarJ70v_evV4p9s28JEzm-xmYT1W9FHwjZWPehDgM8wY48I3ecl7LJ9WpqGu1lgDq6T_vk-qslGu-HGWklPp5dSIl34IQ4rT61aZxjz0VT-PEvvdYBnzLdlfEflCPt-wDTmlkcWTToYSeWEiZtSmnEfcxz4V9jIWwEAMuDNtlwmlYUC-qZwH7Qmf396r6-fnTrv26vvj25bx9f7H2SsG0BkIpAYN3ZDh1WkJHQXmPwdQEHfcgQXOstRbkhHNYB2-8lKrDhmsX5Ko6P3K7hNf2JscB861NGO1dIeVLi3mKvicLwYGXtZIKvNpq1zglfEPagDecO7-w3h1ZN7MbqDtsJGP_CPr4Z4xX9jLt7VZLo5fdrqpX94Ccfs9UJjvEZbF9jyOluVhQGrhpwIilVRxbfU6lZAoPYwS3B7_2zq89-LVHv0umOWb-kEuh-Eijp4fc4ldvdc3BHFSLNk44xTS2aR6nJfr6_6PyL6PduSg</recordid><startdate>20200923</startdate><enddate>20200923</enddate><creator>Ouyang, Jing</creator><creator>Isnard, Stephane</creator><creator>Lin, John</creator><creator>Fombuena, Brandon</creator><creator>Peng, Xiaorong</creator><creator>Routy, Jean-Pierre</creator><creator>Chen, Yaokai</creator><general>Frontiers Media Sa</general><general>Frontiers Media S.A</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2596-969X</orcidid></search><sort><creationdate>20200923</creationdate><title>Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment</title><author>Ouyang, Jing ; Isnard, Stephane ; Lin, John ; Fombuena, Brandon ; Peng, Xiaorong ; Routy, Jean-Pierre ; Chen, Yaokai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-2ea332afcbe90ed532def4ccaf96e2d0c23250a6551eb1bba6fc9c334da805bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>antibody</topic><topic>convalescent plasma therapy</topic><topic>coronavirus disease 2019</topic><topic>Immunology</topic><topic>immunotherapy</topic><topic>Life Sciences & Biomedicine</topic><topic>Science & Technology</topic><topic>severe acute respiratory syndrome coronavirus-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ouyang, Jing</creatorcontrib><creatorcontrib>Isnard, Stephane</creatorcontrib><creatorcontrib>Lin, John</creatorcontrib><creatorcontrib>Fombuena, Brandon</creatorcontrib><creatorcontrib>Peng, Xiaorong</creatorcontrib><creatorcontrib>Routy, Jean-Pierre</creatorcontrib><creatorcontrib>Chen, Yaokai</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ouyang, Jing</au><au>Isnard, Stephane</au><au>Lin, John</au><au>Fombuena, Brandon</au><au>Peng, Xiaorong</au><au>Routy, Jean-Pierre</au><au>Chen, Yaokai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment</atitle><jtitle>Frontiers in immunology</jtitle><stitle>FRONT IMMUNOL</stitle><date>2020-09-23</date><risdate>2020</risdate><volume>11</volume><spage>570063</spage><epage>570063</epage><pages>570063-570063</pages><artnum>570063</artnum><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Coronavirus disease 2019 (COVID-19) is a pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most infected people have mild or moderate symptoms and recover without the need for extensive treatment. However, for seriously ill patients, no specific treatments are currently available. Convalescent plasma therapy (CPT), a passive immunotherapy, involves infusing plasma from recovered people into actively infected people, and is thought to be a specific intervention to improve outcome in patients with severe COVID-19. The presumed mechanism involves neutralizing antibodies and antibody dependent cytotoxicity/phagocytosis. Previous CPT trials showed an effect in SARS and pilot studies suggest CPT is an effective and safe strategy for seriously ill COVID-19 patients. CPT is currently being tested in large randomized clinical trials. Herein, we critically review the mechanism, applications and the challenges for CPT in the treatment of severe COVID-19, paving the way toward vaccine and immunotherapy development.</abstract><cop>LAUSANNE</cop><pub>Frontiers Media Sa</pub><pmid>33072111</pmid><doi>10.3389/fimmu.2020.570063</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2596-969X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1664-3224 |
| ispartof | Frontiers in immunology, 2020-09, Vol.11, p.570063-570063, Article 570063 |
| issn | 1664-3224 1664-3224 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7539593 |
| source | PubMed Central Free; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | antibody convalescent plasma therapy coronavirus disease 2019 Immunology immunotherapy Life Sciences & Biomedicine Science & Technology severe acute respiratory syndrome coronavirus-2 |
| title | Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T21%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Convalescent%20Plasma:%20The%20Relay%20Baton%20in%20the%20Race%20for%20Coronavirus%20Disease%202019%20Treatment&rft.jtitle=Frontiers%20in%20immunology&rft.au=Ouyang,%20Jing&rft.date=2020-09-23&rft.volume=11&rft.spage=570063&rft.epage=570063&rft.pages=570063-570063&rft.artnum=570063&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2020.570063&rft_dat=%3Cproquest_pubme%3E2452098291%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2452098291&rft_id=info:pmid/33072111&rft_doaj_id=oai_doaj_org_article_2fb2c364342c475b8b41c8e592c900bc&rfr_iscdi=true |